Peter has over 15 years of experience as general corporate and transactional counsel, providing legal and strategic advice to public and private companies, boards of directors, investors, and significant stakeholders in diverse industries. Peter is recognized in The Best Lawyers in Canada 2022 directory as a leading Corporate Governance, Corporate, and Mergers & Acquisitions Lawyer. Peter has served as an executive, board member, and advisor to numerous not-for-profit and community organizations, including the Canadian Bar Association and Canadian Cancer Society. Peter is also a past Chair of Farris’ Securities and Mergers & Acquisitions practice group meetings.
Tekmira Pharmaceuticals Corporation (“Tekmira”) completed a merger of equals with OnCore Biopharma, Inc. (“OnCore”) whereby OnCore merged with a wholly-owned subsidiary of Tekmira. As a result of the merger, stockholders of OnCore hold approximately fifty per cent (50%) of the total number of outstanding shares of capital stock of Tekmira. The implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, was approximately USD$750 million and at time of closing USD$964 million.